TN2009000093A1 - Pharmaceutical compositions comprising nilotinib or its salt - Google Patents

Pharmaceutical compositions comprising nilotinib or its salt

Info

Publication number
TN2009000093A1
TN2009000093A1 TN2009000093A TN2009000093A TN2009000093A1 TN 2009000093 A1 TN2009000093 A1 TN 2009000093A1 TN 2009000093 A TN2009000093 A TN 2009000093A TN 2009000093 A TN2009000093 A TN 2009000093A TN 2009000093 A1 TN2009000093 A1 TN 2009000093A1
Authority
TN
Tunisia
Prior art keywords
salt
nilotinib
pharmaceutical compositions
granules
produced
Prior art date
Application number
TN2009000093A
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000093A1 publication Critical patent/TN2009000093A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TN2009000093A 2006-09-27 2009-03-19 Pharmaceutical compositions comprising nilotinib or its salt TN2009000093A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (fr) 2006-09-27 2006-09-27 Composition pharmaceutique comprenant de la nilotinib ou son sel
PCT/EP2007/060165 WO2008037716A2 (fr) 2006-09-27 2007-09-25 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
TN2009000093A1 true TN2009000093A1 (en) 2010-08-19

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000093A TN2009000093A1 (en) 2006-09-27 2009-03-19 Pharmaceutical compositions comprising nilotinib or its salt

Country Status (35)

Country Link
US (2) US8293756B2 (fr)
EP (4) EP1923053A1 (fr)
JP (2) JP5567340B2 (fr)
KR (2) KR20090076931A (fr)
CN (2) CN101516344A (fr)
AR (1) AR062980A1 (fr)
AU (1) AU2007301977B2 (fr)
BR (1) BRPI0719438B1 (fr)
CA (1) CA2662571C (fr)
CL (1) CL2007002766A1 (fr)
CO (1) CO6160288A2 (fr)
CY (2) CY1117021T1 (fr)
DK (2) DK2068839T3 (fr)
ES (3) ES2951547T3 (fr)
FI (2) FI3984528T3 (fr)
HK (1) HK1133193A1 (fr)
HR (2) HRP20151383T4 (fr)
HU (2) HUE028204T2 (fr)
IL (1) IL197496A (fr)
JO (1) JO3757B1 (fr)
LT (1) LT3984528T (fr)
MA (1) MA30807B1 (fr)
MX (1) MX2009003184A (fr)
MY (1) MY148237A (fr)
NO (2) NO347404B1 (fr)
NZ (1) NZ575317A (fr)
PE (2) PE20081379A1 (fr)
PL (2) PL2068839T5 (fr)
PT (2) PT3984528T (fr)
RU (1) RU2469707C2 (fr)
SI (2) SI2068839T2 (fr)
TN (1) TN2009000093A1 (fr)
TW (3) TWI540128B (fr)
WO (1) WO2008037716A2 (fr)
ZA (1) ZA200901511B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
WO2011036305A2 (fr) 2009-09-28 2011-03-31 Medizinische Universität Wien Nouvelle utilisation des inhibiteurs de pdgf-bêta
RU2012120901A (ru) * 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012164578A1 (fr) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions et procédés de préparation de formulations de nilotinib à libération immédiate
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
WO2013063000A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Procédé de traitement de tumeurs stromales gastro-intestinales
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
KR20140093230A (ko) * 2011-11-14 2014-07-25 노파르티스 아게 즉시 방출 4-메틸-3-[[4-(3-피리디닐)-2-피리미디닐]아미노]-n-[5-(4-메틸-1h-이미다졸-1-일)-3-(트리플루오로메틸)페닐] 벤즈아미드 제제
CN104427986A (zh) 2012-07-11 2015-03-18 诺华股份有限公司 治疗胃肠道基质瘤的方法
WO2014174496A1 (fr) 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Forme posologique orale solide de produit pharmaceutique à rétention gastrique de nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
SI3189045T1 (sl) 2014-08-11 2022-05-31 Sun Pharmaceutical Industries Limited Nove soli nilotiniba in njih polimorfi
US10045987B2 (en) * 2014-08-28 2018-08-14 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
US20200163962A1 (en) * 2016-03-17 2020-05-28 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (fr) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Composition pharmaceutique liquide stable de nilotinib
EP4122452A1 (fr) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant du nilotinib et son procédé de fabrication
EP4260848A1 (fr) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DK0925294T6 (da) 1996-07-24 2018-08-20 Celgene Corp Substituerede 2-(2,6-dioxopiperidin-3-yl)phthalimider og -1-oxoisoindoliner samt fremgangsmåde til reduktion af tnf-alpha-niveauer
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
ES2310166T3 (es) 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
CN1203852C (zh) * 1999-12-08 2005-06-01 法马西亚公司 维得克西组合物
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
US20060257482A1 (en) * 2002-06-07 2006-11-16 Patrik Kumar Modified release, multiple unit drug delivery systems
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1565258B1 (fr) * 2002-11-26 2011-12-14 Universiteit Gent Procede et appareil pour la granulation continue par voie humide de materiau pulverulent
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
CA2532931A1 (fr) * 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (fr) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Enrobage intime d'ibuprofene avec des poloxameres afin d'ameliorer la dissolution aqueuse
WO2006013444A1 (fr) 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
US20070298111A1 (en) * 2004-10-01 2007-12-27 Eisai R&D Management Co., Ltd. Fine Particle-Containing Composition and Manufacturing Method Therefor
WO2006066932A1 (fr) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Composition pharmaceutique stable comprenant une substance active sous la forme d’une solution solide
CA2594687C (fr) * 2005-01-28 2013-10-29 Novartis Ag Utilisation de pyrimidylaminobenzamides destinees au traitement de maladies qui repondent a la modulation de l'activite tie.2 kinase
KR20070106036A (ko) * 2005-02-25 2007-10-31 노파르티스 아게 Ｂｃｒ-ａｂｌ 및 ｒａｆ 억제제의 제약 조합물
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel

Also Published As

Publication number Publication date
TW201418244A (zh) 2014-05-16
WO2008037716A2 (fr) 2008-04-03
PL2068839T3 (pl) 2016-06-30
NO20220946A1 (no) 2009-04-24
NZ575317A (en) 2011-12-22
PE20081379A1 (es) 2008-11-27
US8501760B2 (en) 2013-08-06
JP2010504942A (ja) 2010-02-18
EP3009128B1 (fr) 2023-07-05
RU2009115782A (ru) 2010-11-10
CN104306350A (zh) 2015-01-28
PE20120626A1 (es) 2012-06-07
EP2068839B2 (fr) 2022-10-12
ES2556625T5 (es) 2023-03-02
TW201418245A (zh) 2014-05-16
ZA200901511B (en) 2010-02-24
US20130023549A1 (en) 2013-01-24
BRPI0719438B1 (pt) 2022-04-19
KR101598747B1 (ko) 2016-03-02
SI3984528T1 (sl) 2023-09-29
ES2951547T3 (es) 2023-10-23
JO3757B1 (ar) 2021-01-31
PT2068839E (pt) 2015-12-30
TWI540128B (zh) 2016-07-01
MA30807B1 (fr) 2009-10-01
KR20090076931A (ko) 2009-07-13
US8293756B2 (en) 2012-10-23
US20100087463A1 (en) 2010-04-08
KR20140121903A (ko) 2014-10-16
IL197496A0 (en) 2009-12-24
RU2469707C2 (ru) 2012-12-20
EP3984528A1 (fr) 2022-04-20
HK1133193A1 (en) 2010-03-19
HRP20230753T3 (hr) 2023-10-27
SI2068839T2 (sl) 2023-01-31
FI3984528T3 (fi) 2023-07-27
MX2009003184A (es) 2009-04-03
FI2068839T4 (fi) 2023-01-31
CN101516344A (zh) 2009-08-26
HUE028204T2 (en) 2016-12-28
EP2068839A2 (fr) 2009-06-17
JP2014065715A (ja) 2014-04-17
ES2556625T3 (es) 2016-01-19
BRPI0719438A2 (pt) 2013-12-10
HUE063083T2 (hu) 2023-12-28
AU2007301977B2 (en) 2011-09-08
EP1923053A1 (fr) 2008-05-21
CY1117021T1 (el) 2017-04-05
NO346639B1 (no) 2022-11-07
CA2662571C (fr) 2016-09-27
EP2068839B1 (fr) 2015-09-23
DK3984528T3 (da) 2023-07-31
CO6160288A2 (es) 2010-05-20
EP3984528B1 (fr) 2023-07-05
CY1126116T1 (el) 2023-11-15
HRP20151383T4 (hr) 2023-03-03
JP5567340B2 (ja) 2014-08-06
IL197496A (en) 2016-04-21
SI2068839T1 (sl) 2016-02-29
PL2068839T5 (pl) 2023-01-30
CA2662571A1 (fr) 2008-04-03
MY148237A (en) 2013-03-29
TW200821298A (en) 2008-05-16
EP3009128A1 (fr) 2016-04-20
TWI428333B (zh) 2014-03-01
NO347404B1 (no) 2023-10-16
HRP20151383T1 (hr) 2016-01-15
AR062980A1 (es) 2008-12-17
WO2008037716A3 (fr) 2008-07-17
AU2007301977A1 (en) 2008-04-03
PT3984528T (pt) 2023-08-07
PL3984528T3 (pl) 2023-08-28
CL2007002766A1 (es) 2008-08-08
DK2068839T3 (da) 2016-01-11
NO20091501L (no) 2009-04-24
LT3984528T (lt) 2023-08-10
ES2957912T3 (es) 2024-01-29

Similar Documents

Publication Publication Date Title
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
WO2006134021A3 (fr) Procede de preparation de nouveaux sels de tiotropium, nouveaux sels de tiotropium en tant que tels et compositions pharmaceutiques associees
EP2201011A4 (fr) Nouveaux composés présentant des squelettes d'indazole, méthodes de préparation de ceux-ci et composition pharmaceutique les contenant
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
IL193774A0 (en) Pharmaceutical compositions containing a 3,5-seco-4-norcholestane derivative
HK1096386A1 (en) Indanyl-piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
WO2009022327A3 (fr) Nouveau procédé de préparation de lévocétirizine de pureté élevée et de ses sels
ZA200803152B (en) Oramucosal pharmaceutical dosage form
ZA200603810B (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
SI2081904T1 (sl) Aripiprazol hemifumarat in postopek za njegovo pripravo
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
HK1096097A1 (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
WO2007071444A3 (fr) Esomeprazole arginine
ZA200809206B (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same
SI1906926T1 (sl) Farmacevtski sestavek, ki obsega 2,3-dihidro-6-nitroimidazo(2,1-b)oksazolne derivate
IL192963A0 (en) Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
WO2009121946A3 (fr) Procédé de préparation de clopidogrel optiquement enrichi
ZA200902413B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ZA200805656B (en) Prodrug ER²-selective substances, methods for the production thereof and pharmaceutical compositions containing said compounds
WO2007093168A3 (fr) Composition pharmaceutique contenant de l'irbesartan à libération rapide